Alvotech (ALVO)
| Market Cap | 1.86B |
| Revenue (ttm) | 36.77M |
| Net Income (ttm) | -101.50M |
| Shares Out | 210.60M |
| EPS (ttm) | 0.01 |
| PE Ratio | 1,262.86 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,556 |
| Open | 8.67 |
| Previous Close | 9.00 |
| Day's Range | 8.64 - 9.57 |
| 52-Week Range | 8.64 - 14.04 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ALVO
Oaktree Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the industrial and consumer sectors. The company was incorporated in 2020 and is based in Los Angeles, California. [Read more...]
Financial Performance
In 2021, Alvotech's revenue was $36.77 million, a decrease of -44.80% compared to the previous year's $66.62 million. Losses were -$101.50 million, -40.31% less than in 2020.
Financial StatementsNews
Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and...
REYKJAVIK, Iceland, June 22, 2022 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today announced...
Supplement to the Company Description
In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC), Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June 2022. ...
Publication of a Company Description and Intended Listing on First North Iceland
Alvotech, a public limited liability company (société anonyme), incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxe...
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16
REYKJAVIK, ICELAND & NEW YORK--(BUSINESS WIRE)---- $ALVO #ALVO--Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide today ...
Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination
REYKJAVIK, Iceland & LOS ANGELES--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech S.A.”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patien...
Oaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its...
LOS ANGELES--(BUSINESS WIRE)--Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions to the closing of its pending business com...
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference ...
REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today...
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, today...
Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meetin...
REYKJAVIK, Iceland & LOS ANGELES--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech S.A.”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines ...
Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange
REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldw...
Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® b...
REYKJAVIK, Iceland & BAD VILBEL, Germany--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicin...
FDA Accepts Alvotech's BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Can...
REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldw...
Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan
REYKJAVIK, Iceland & TOKYO--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patient...